TherapeuticsMD, Drug Prices & Medicare Spending
TherapeuticsMD manufactures 2 drugs tracked by Medicare Part D with total spending of $212.0M.
TherapeuticsMD Drugs, Ranked by Medicare Spending
| # | Drug | Generic Name | Cost/Claim | Generic? |
|---|---|---|---|---|
| 1 | Imvexxy | Estradiol (vaginal insert) | $142.00 | Yes |
| 2 | Bijuva | Estradiol/Progesterone | $143.00 | Yes |
Frequently Asked Questions
TherapeuticsMD manufactures 2 drugs tracked by Medicare Part D, with total annual spending of $212.0M.
Bijuva (Estradiol/Progesterone) is the most expensive at $143.00 per claim.
2 of 2 TherapeuticsMD drugs (100%) have generic alternatives available. Generic drugs can save patients 30-80% compared to brand-name versions.
The this entity record above pulls directly from CMS Medicare Part D Drug Spending data. What follows is the per-entity context — how this entity sits in the broader U.S. Medicare prescription-drug pricing distribution and which underlying factors drive the headline numbers.
Every number on this page links back to CMS Medicare Part D Drug Spending data; the methodology page describes the inputs, refresh cadence, and known limitations of the underlying data product.
For readers using this page as a decision input, the related-entity pages elsewhere on the site provide the comparison set. The most useful comparison for this entity is typically a peer within U.S. prescription drugs with similar size, similar exposure, or similar geography — not the national-level summary alone.
Source: CMS Medicare Part D Spending, 2026.